Compare General Motors Company (GM) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Incyte Corporation — how do they compare? General Motors Company trades at $77.11 (market cap $70.01B), while Incyte Corporation trades at $116.23 (market cap $22.99B). The key difference: General Motors Company is far larger — about 3× Incyte Corporation's market cap, and General Motors Company pays a 0.93% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| GM | INCY | |
|---|---|---|
Market Cap | $70.01B | $22.99B |
Sector | Consumer Cyclical | Health |
52-Week High | $86.38 | $118.52 |
52-Week Low | $48.89 | $67.38 |
Enterprise Value | $173.34B | $19.01B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $76.87, up 0.2% daily, with a neutral technical signal. The company shows strong operational cash flow of $26.87B in 2025 and has beaten earnings estimates for three consecutive quarters. Valuation metrics appear attractive with P/S of 0.4 and P/B of 1.12, while analyst consensus remains bullish with a $102 price target representing 33% upside potential.
GM presents a value opportunity with depressed valuation multiples despite recent earnings beats and solid cash generation. Key risks include declining profit margins (1.38% net margin in 2025), competitive pressures in the EV transition, and elevated debt levels. The stock's appeal hinges on margin stabilization and successful execution of strategic initiatives amid industry headwinds.
Incyte (INCY) trades at $114.88, up 0.57% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive Phase 1/2 data for VGA039 and European regulatory progress for Opzelura highlight pipeline momentum, while Q1 2026 EPS of $1.81 beat expectations by 35%.
The outlook remains positive with 52% analyst buy ratings and a consensus price target of $112.78, though risks include pipeline execution and competitive pressures. Revenue growth to $5.4B projected for 2026 supports valuation, but investors should monitor Q2 earnings due July 28, 2026 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
